An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04436471|
Recruitment Status : Completed
First Posted : June 18, 2020
Last Update Posted : August 12, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The purpose of the study is to assess safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac ", a solution for intramuscular administration, with the participation of healthy volunteers
Study objectives A safety and tolerability assessment of the drug "Gam-COVID-Vac ", solution for intramuscular administration, using single dose of each component (Stage 1).
A safety and tolerability assessment of the drug "Gam-COVID-Vac ", solution for intramuscular administration, using prime-boost immunization according to the proposed scheme (Stage 2).
Post-vaccination immunity assessment at different time points after vaccination by:
- Determination of antigen-specific antibody titer in blood serum by ELISA by comparison with baseline values before the vaccine administration and at days 14, 21, 28, and 42 after vaccination (hereinafter, the countdown comes from the first time of the vaccine administration);
- Determination of virus neutralizing antibody titer before and at days 14, 28, and 42 after vaccination;
- Determination of antigen-specific cellular immunity (specific T-cell immunity) before the vaccine administration and at days 14 and 28 after vaccination.
|Condition or disease||Intervention/treatment||Phase|
|Preventive Immunization COVID-19||Biological: Gam-COVID-Vac||Phase 1 Phase 2|
An open two stage non-randomized Phase 1 study with the participation of healthy volunteers. This clinical trial is an open study of safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac ", ly solution for intramuscular administration, with the participation of healthy volunteers.
- the First group, 9 volunteers, will receive the drug, a solution for intramuscular administration, in the mode of single immunization with component 1 in a full therapeutic dose.
- the Second group, 9 volunteers, will receive the drug, a solution for intramuscular administration, in the mode of single immunization with component 2 in the full therapeutic dose.
The studied drugs will be administered to a total of 18 volunteers in a hospital setting and after administration, the drug's safety will be continuously monitored for 5 days. Based on the results of the safety assessment, the Chief investigator decides to proceed to the second stage of the study on the 5th day after the introduction of the studied drugs.
Second stage The second stage will include 20 volunteers and three understudies. Volunteers of the second stage will be vaccinated no earlier than 5 days after vaccination of participants of the first stage.
Volunteers participating in the second stage of the study (a total of 20 people) will receive the study drug according to the booster scheme: the introduction of component 1 will be carried out on day 1, and component 2-on the 21st day of the study. Follow-up will be carried out during 4 visits: on 7, 14, 28, 42 days after administration of the drug, and phone calls at days 90 and 180
Throughout the inpatient observation and the follow-up period of visits during the entire study, safety information will be collected
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||An open, prospective, two-stage, non-randomized, first-phase study involving healthy volunteers|
|Masking:||None (Open Label)|
|Official Title:||An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers|
|Actual Study Start Date :||June 17, 2020|
|Actual Primary Completion Date :||August 3, 2020|
|Actual Study Completion Date :||August 10, 2020|
Experimental: Component 1
rAd26 Component, 1 vaccination
Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene
adenoviral-based vaccine against SARS-CoV-2
Experimental: Component 2
rAd5 Component, 1 vaccination
Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
adenoviral-based vaccine against SARS-CoV-2
Experimental: Prime-Boost Immunization
Day 1 rAd26 Component Day 21 rAd5 Component
adenoviral-based vaccine against SARS-CoV-2
- Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days [ Time Frame: at days 0,14, 21, 28, 42 ]Determination of antibody levels against the SARS-CoV-2 glycoprotein S measured by an ELISA vs. baseline values
- Number of Participants With Adverse Events [ Time Frame: through the whole study, an average of 180 days ]Determination of Number of Participants With Adverse Events
- Changing of of virus neutralizing antibody titer [ Time Frame: at days 0,14, 28, 42 ]Determination of virus neutralizing antibody titer
- Changing of antigen-specific cellular immunity level [ Time Frame: at days 0,14, 42 ]Determination of antigen-specific cellular immunity (specific T-cell immunityin particular, IFN-gamma production or lymphoproliferation)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 60 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- males and females within the age range from 18 to 60 years;
- written informed consent;
- subject body mass index (BMI): 18.5 ≤ BMI ≤ 30;
- negative PCR test results for SARS-CoV-2 (during the screening);
- no history of COVID-2019 disease;
- no contacts of volunteers with patients with COVID-2019 for at least 14 days;
- negative test results for IgM and IgG antibodies to SARS-CoV-2;
- subject agrees to use effective contraceptive methods during the entire period of participation in the study;
- absence of acute infectious diseases at the time of vaccine administration and 14 days before vaccination;
- negative pregnancy test of blood or urine (for women of childbearing age);
- subject has negative tests for HIV, hepatitis B and С, syphilis or confirmed medical history;
- subject has a negative result of the urine test for residual narcotic drugs;
- negative test for alcohol in exhaled air;
- the absence of malignant diseases of any nature and localization;
- in medical history and based on the screening results, subject has no diseases or pathologies of the gastrointestinal system, liver, kidneys, cardiovascular system and blood, CNS, musculoskeletal system, urogenital, immune and endocrine systems that from the point of view of the researcher and/or of the organizer of the study, may affect the safety of the volunteer and the evaluation of the study results (clinical, instrumental and laboratory tests did not reveal diseases or clinically significant deviations).
- volunteer involvement in another study over the last 90 days;
- any vaccination over the last 30 days;
- history of COVID-2019 disease;
- positive PCR test results for SARS-CoV-2 (during the screening);
- positive test results for IgM and IgG antibodies to SARS-CoV-2;
- health staff in contact with people with COVID-2019;
- respiratory symptoms in the last 14 days;
- the administration of immunoglobulins or other blood products in the last 3 months;
- regular current or past use of narcotic drugs;
- subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study;
- pregnancy or breast feeding;
- exacerbation of allergic diseases at the time of vaccination;
- subject has systolic blood pressure less than 100 mm Hg or greater than 139 mm Hg; diastolic blood pressure less than 60 mm Hg or greater than 90 mm Hg; heart rate lower than 60 beats per minute or above 100 beats per minute;
- a burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.);
- a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship;
- subject smokes more than 10 cigarettes per day;
- alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug;
- planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug;
- the presence of an associated disease that may affect the assessment of the results of the study;
- any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04436471
|Main military clinical hospital named after academician N. N. Burdenko|
|Moscow, Russian Federation|
|Responsible Party:||Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|
|Other Study ID Numbers:||
|First Posted:||June 18, 2020 Key Record Dates|
|Last Update Posted:||August 12, 2020|
|Last Verified:||June 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases